- Home
- Publications
- Publication Search
- Publication Details
Title
The Identification of Immunological Biomarkers in Kidney Cancers
Authors
Keywords
-
Journal
Frontiers in Oncology
Volume 8, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2018-11-02
DOI
10.3389/fonc.2018.00456
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Renal cell carcinoma in one year: Going inside the news of 2017 – A report of the main advances in RCC cancer research
- (2018) Claudia Mosillo et al. CANCER TREATMENT REVIEWS
- Tivozanib for the treatment of renal cell carcinoma
- (2018) Matteo Santoni et al. EXPERT OPINION ON PHARMACOTHERAPY
- IMmotion151: A Randomized Phase III Study of Atezolizumab Plus Bevacizumab vs Sunitinib in Untreated Metastatic Renal Cell Carcinoma (mRCC)
- (2018) Robert J. Motzer et al. JOURNAL OF CLINICAL ONCOLOGY
- Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
- (2018) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Potential impact of PD-L1 (SP-142) immunohistochemical heterogeneity in clear cell renal cell carcinoma immunotherapy
- (2018) José I. López et al. PATHOLOGY RESEARCH AND PRACTICE
- Drug Combo Bests Sunitinib in RCC
- (2018) Cancer Discovery
- Comprehensive molecular and immunohistochemical analysis of advanced renal cell carcinoma patients treated with mTOR inhibitors.
- (2018) Jesús GarcÃa-Donas et al. JOURNAL OF CLINICAL ONCOLOGY
- Alterations in key clear cell renal cell carcinoma (RCC) genes to refine patient prognosis.
- (2018) Dominick Bossé et al. JOURNAL OF CLINICAL ONCOLOGY
- Hypermutated tumours in the era of immunotherapy: The paradigm of personalised medicine
- (2017) Laetitia Nebot-Bral et al. EUROPEAN JOURNAL OF CANCER
- Clear Cell Type A and B Molecular Subtypes in Metastatic Clear Cell Renal Cell Carcinoma: Tumor Heterogeneity and Aggressiveness
- (2017) Daniel J. Serie et al. EUROPEAN UROLOGY
- Evolution of Circulating Tumor DNA Profile from First-line to Subsequent Therapy in Metastatic Renal Cell Carcinoma
- (2017) Sumanta K. Pal et al. EUROPEAN UROLOGY
- PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project
- (2017) Fred R. Hirsch et al. Journal of Thoracic Oncology
- VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer
- (2017) Jianjun Gao et al. NATURE MEDICINE
- Tumor Mutational Burden and Response Rate to PD-1 Inhibition
- (2017) Mark Yarchoan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
- (2017) Bertrand Routy et al. SCIENCE
- Genito-urinary genomics and emerging biomarkers for immunomodulatory cancer treatment
- (2017) Thomas Gevaert et al. SEMINARS IN CANCER BIOLOGY
- Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression
- (2017) Angel Garcia-Diaz et al. Cell Reports
- PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome
- (2017) Hashem O. Alsaab et al. Frontiers in Pharmacology
- A Quantitative Comparison of Antibodies to Programmed Cell Death 1 Ligand 1
- (2017) Patricia Gaule et al. JAMA Oncology
- A Prospective, Multi-institutional, Pathologist-Based Assessment of 4 Immunohistochemistry Assays for PD-L1 Expression in Non–Small Cell Lung Cancer
- (2017) David L. Rimm et al. JAMA Oncology
- Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†
- (2016) B. Escudier et al. ANNALS OF ONCOLOGY
- Testing PD-1/PD-L1 Expression in Cancer Therapy: Pathologic Insights and Economic Sustainability
- (2016) Rodolfo Montironi et al. ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE
- Anti-PD-L1 treatment enhances antitumor effect of everolimus in a mouse model of renal cell carcinoma
- (2016) Yukiyoshi Hirayama et al. CANCER SCIENCE
- Economic sustainability of anti-PD-1 agents nivolumab and pembrolizumab in cancer patients: Recent insights and future challenges
- (2016) Francesca Tartari et al. CANCER TREATMENT REVIEWS
- Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma
- (2016) Toni K. Choueiri et al. CLINICAL CANCER RESEARCH
- An Overview of Emerging Immunotargets of Genitourinary Tumors
- (2016) Rodolfo Montironi et al. CURRENT DRUG TARGETS
- Editorial (Thematic Issue: Emerging Immunotargets in Genitourinary Tumors)
- (2016) Rodolfo Montironi et al. CURRENT DRUG TARGETS
- Emerging Immunotargets in Metastatic Renal Cell Carcinoma
- (2016) John Kucharczyk et al. CURRENT DRUG TARGETS
- Genomic Characterization of Renal Cell Carcinoma with Sarcomatoid Dedifferentiation Pinpoints Recurrent Genomic Alterations
- (2016) Gabriel G. Malouf et al. EUROPEAN UROLOGY
- The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs—Part A: Renal, Penile, and Testicular Tumours
- (2016) Holger Moch et al. EUROPEAN UROLOGY
- Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation
- (2016) Ana C. Anderson et al. IMMUNITY
- Integrated genomic correlates of response to PD-1 inhibitor nivolumab in metastatic renal cell carcinoma (mRCC).
- (2016) Guillermo de Velasco et al. JOURNAL OF CLINICAL ONCOLOGY
- Atezolizumab, an Anti–Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia Study
- (2016) David F. McDermott et al. JOURNAL OF CLINICAL ONCOLOGY
- Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma
- (2016) NEW ENGLAND JOURNAL OF MEDICINE
- Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma
- (2016) Jesse M. Zaretsky et al. NEW ENGLAND JOURNAL OF MEDICINE
- Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints
- (2016) Shohei Koyama et al. Nature Communications
- Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations
- (2016) Daniel Sanghoon Shin et al. Cancer Discovery
- Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non–Small Cell Lung Cancer
- (2016) Valsamo Anagnostou et al. Cancer Discovery
- Performance evaluation for rapid detection of pan-cancer microsatellite instability with MANTIS
- (2016) Esko A. Kautto et al. Oncotarget
- Systemic immune-inflammation index predicts the clinical outcome in patients with metastatic renal cell cancer treated with sunitinib
- (2016) Cristian Lolli et al. Oncotarget
- Multilevel Genomics-Based Taxonomy of Renal Cell Carcinoma
- (2016) Fengju Chen et al. Cell Reports
- The Intratumoral Balance between Metabolic and Immunologic Gene Expression Is Associated with Anti-PD-1 Response in Patients with Renal Cell Carcinoma
- (2016) M. L. Ascierto et al. Cancer Immunology Research
- Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 Blockade
- (2016) D. B. Johnson et al. Cancer Immunology Research
- Tumor Mutational Load and Immune Parameters across Metastatic Renal Cell Carcinoma Risk Groups
- (2016) G. de Velasco et al. Cancer Immunology Research
- Nivolumab in renal cell carcinoma: latest evidence and clinical potential
- (2016) Camille Mazza et al. Therapeutic Advances in Medical Oncology
- PD-1 blockade therapy in renal cell carcinoma: Current studies and future promises
- (2015) F. Massari et al. CANCER TREATMENT REVIEWS
- Anti-programmed Cell Death Protein 1 (PD-1) Antibody Nivolumab Leads to a Dramatic and Rapid Response in Papillary Renal Cell Carcinoma with Sarcomatoid and Rhabdoid Features
- (2015) Daniel M. Geynisman EUROPEAN UROLOGY
- Understanding Pathologic Variants of Renal Cell Carcinoma: Distilling Therapeutic Opportunities from Biologic Complexity
- (2015) Brian Shuch et al. EUROPEAN UROLOGY
- The immunocheckpoints in modern oncology: the next 15 years
- (2015) Francesco Massari et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- New toxicity profile for novel immunotherapy agents: focus on immune-checkpoint inhibitors
- (2015) C Ciccarese et al. Expert Opinion on Drug Metabolism & Toxicology
- Present and future of personalized medicine in adult genitourinary tumors
- (2015) Chiara Ciccarese et al. Future Oncology
- Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial
- (2015) Robert J. Motzer et al. JOURNAL OF CLINICAL ONCOLOGY
- Programmed Death-Ligand 1 Immunohistochemistry in Lung Cancer: In what state is this art?
- (2015) Keith M. Kerr et al. Journal of Thoracic Oncology
- Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial
- (2015) Robert J Motzer et al. LANCET ONCOLOGY
- PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
- (2015) Dung T. Le et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma
- (2015) Toni K. Choueiri et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
- (2015) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Intrinsic and extrinsic control of expression of the immunoregulatory molecule PD-L1 in epithelial cells and squamous cell carcinoma
- (2015) Patcharee Ritprajak et al. ORAL ONCOLOGY
- Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
- (2015) N. A. Rizvi et al. SCIENCE
- Prognostic Role of PD-L1 Expression in Renal Cell Carcinoma. A Systematic Review and Meta-Analysis
- (2015) Roberto Iacovelli et al. Targeted Oncology
- Axitinib induces DNA damage response leading to senescence, mitotic catastrophe, and increased NK cell recognition in human renal carcinoma cells
- (2015) Maria Beatrice Morelli et al. Oncotarget
- Computational analysis of the mutations in BAP1, PBRM1 and SETD2 genes reveals the impaired molecular processes in renal cell carcinoma
- (2015) Francesco Piva et al. Oncotarget
- Immunotherapy in Metastatic Renal Cell Carcinoma: A Comprehensive Review
- (2015) Rachna Raman et al. Biomed Research International
- Differential Expression of PD-L1 between Primary and Metastatic Sites in Clear-Cell Renal Cell Carcinoma
- (2015) M. Callea et al. Cancer Immunology Research
- Chromosome 9p deletion in clear cell renal cell carcinoma predicts recurrence and survival following surgery
- (2014) I El-Mokadem et al. BRITISH JOURNAL OF CANCER
- The Somatic Genomic Landscape of Chromophobe Renal Cell Carcinoma
- (2014) Caleb F. Davis et al. CANCER CELL
- Correlation of PD-L1 Tumor Expression and Treatment Outcomes in Patients with Renal Cell Carcinoma Receiving Sunitinib or Pazopanib: Results from COMPARZ, a Randomized Controlled Trial
- (2014) T. K. Choueiri et al. CLINICAL CANCER RESEARCH
- Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti-PD-1 Therapy
- (2014) J. M. Taube et al. CLINICAL CANCER RESEARCH
- ClearCode34: A Prognostic Risk Predictor for Localized Clear Cell Renal Cell Carcinoma
- (2014) Samira A. Brooks et al. EUROPEAN UROLOGY
- Loss of MLH1 confers resistance to PI3Kβ inhibitors in renal clear cell carcinoma with SETD2 mutation
- (2014) Chenchen Feng et al. TUMOR BIOLOGY
- Deficiency of MSH2 expression is associated with clear cell renal cell carcinoma
- (2014) KOO HAN YOO et al. Oncology Letters
- The Vigorous Immune Microenvironment of Microsatellite Instable Colon Cancer Is Balanced by Multiple Counter-Inhibitory Checkpoints
- (2014) Nicolas J. Llosa et al. Cancer Discovery
- Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8+ T cells directly within the tumor microenvironment
- (2014) Stefani Spranger et al. Journal for ImmunoTherapy of Cancer
- Heterogeneous drug target expression as possible basis for different clinical and radiological response to the treatment of primary and metastatic renal cell carcinoma: suggestions from bench to bedside
- (2013) Matteo Santoni et al. CANCER AND METASTASIS REVIEWS
- Emerging role of tumor-associated macrophages as therapeutic targets in patients with metastatic renal cell carcinoma
- (2013) Matteo Santoni et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: Final overall survival results and safety update
- (2013) Cora N. Sternberg et al. EUROPEAN JOURNAL OF CANCER
- Spatiotemporal Dynamics of Intratumoral Immune Cells Reveal the Immune Landscape in Human Cancer
- (2013) Gabriela Bindea et al. IMMUNITY
- Role of natural and adaptive immunity in renal cell carcinoma response to VEGFR-TKIs and mTOR inhibitor
- (2013) Matteo Santoni et al. INTERNATIONAL JOURNAL OF CANCER
- Randomized Phase III Trial of Temsirolimus Versus Sorafenib As Second-Line Therapy After Sunitinib in Patients With Metastatic Renal Cell Carcinoma
- (2013) Thomas E. Hutson et al. JOURNAL OF CLINICAL ONCOLOGY
- Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial
- (2013) Robert J Motzer et al. LANCET ONCOLOGY
- Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma
- (2013) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mismatch Repair Proteins hMLH1 and hMSH2 Are Differently Expressed in the Three Main Subtypes of Sporadic Renal Cell Carcinoma
- (2012) Christine Stoehr et al. PATHOBIOLOGY
- Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma
- (2011) Ignacio Varela et al. NATURE
- Frequent mutations of genes encoding ubiquitin-mediated proteolysis pathway components in clear cell renal cell carcinoma
- (2011) Guangwu Guo et al. NATURE GENETICS
- The Effect of Sunitinib on Immune Subsets in Metastatic Clear Cell Renal Cancer
- (2011) Thomas Powles et al. UROLOGIA INTERNATIONALIS
- Phase 3 trial of everolimus for metastatic renal cell carcinoma
- (2010) Robert J. Motzer et al. CANCER
- Role of sorafenib and sunitinib in the induction of expressions of NKG2D ligands in nasopharyngeal carcinoma with high expression of ABCG2
- (2010) Yuxian Huang et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- A Decrease of Regulatory T Cells Correlates With Overall Survival After Sunitinib-based Antiangiogenic Therapy in Metastatic Renal Cancer Patients
- (2010) Olivier Adotevi et al. JOURNAL OF IMMUNOTHERAPY
- Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes
- (2010) Gillian L. Dalgliesh et al. NATURE
- Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitors
- (2009) R Kumar et al. BRITISH JOURNAL OF CANCER
- Sorafenib for Treatment of Renal Cell Carcinoma: Final Efficacy and Safety Results of the Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial
- (2009) Bernard Escudier et al. JOURNAL OF CLINICAL ONCOLOGY
- Implications of mismatch repair genes hMLH1and hMSH2in patients with sporadic renal cell carcinoma
- (2008) Antonio Rubio-Del-Campo et al. BJU INTERNATIONAL
- Sorafenib, but not sunitinib, affects function of dendritic cells and induction of primary immune responses
- (2008) M. M. Hipp et al. BLOOD
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started